Centers | ||
|
|
|
EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Novo Nordisk and Oxford to Develop Drugs to Treat Rheumatoid Arthritis and Other Inflammatory DiseasesNovo Nordisk and Kennedy Institute of Rheumatology at Oxford University have entered into partnership to develop new drugs to treat Rheumatoid Arthritis and other inflammatory disorders. Novo Nordisk will provide research funding support to ten... View all Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all |
No EVENTS for listing |
No Job Posts |
